APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the standard first-line treatment for advanced lung adenocarcinoma (LUAD) cancer patients with activating EGFR mutations. However, most patients show acquired resistance to EGFR-TKIs, thereby resulting in a modest ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Guo-Shou, Li, Mengxia, Xu, Cheng-Xiong, Wang, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208429/
https://www.ncbi.nlm.nih.gov/pubmed/30382076
http://dx.doi.org/10.1038/s41419-018-1162-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208429/
https://www.ncbi.nlm.nih.gov/pubmed/30382076
http://dx.doi.org/10.1038/s41419-018-1162-0

Ejemplares similares